Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18338406 | 0.81 | SMN1; SMN2 (0.34) | CYP1A2KDM4EALDH1A1GLAGAA | |
| SCHEMBL14248952 | 0.69 | CYP1A2 (0.39) | CYP1A2ALDH1A1GAA | |
| SCHEMBL1180242 | 0.68 | CYP1A2 (0.38) | CYP1A2 | |
| SCHEMBL15473978 | 0.67 | — | — | |
| SCHEMBL15473960 | 0.64 | CYP1A2 (0.40) | CYP1A2ALDH1A1GAA | |
| SCHEMBL4497137 | 0.64 | — | — | |
| SCHEMBL4207853 | 0.64 | CDC7 (0.50) | ALDH1A1GAA | |
| SCHEMBL20939379 | 0.63 | HRH3 (0.34) | — | |
| SCHEMBL14249389 | 0.63 | CYP1A2 (0.35) | CYP1A2GAA | |
| SCHEMBL14249114 | 0.63 | CYP1A2 (0.35) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117015539-A | Aminopyridine derivative, preparation method and application thereof | 成都苑东生物制药股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| WO-2023179597-A1 | AMINOPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都苑东生物制药股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| US-20220340592-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2022-10-27 | — | — | US | disclosed |
| CN-108948019-B | Focal adhesion kinase inhibitors and uses thereof | 广东东阳光药业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | ASTRAZENECA AB (SE) | 2022-06-07 | — | — | US | disclosed |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | ASTRAZENECA AB (SE) | 2022-06-07 | — | — | US | disclosed |
| EP-3539961-B1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3539961-B1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210171541-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-06-10 | — | — | US | disclosed |
| US-20210171541-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-06-10 | — | — | US | disclosed |
| EP-3313838-B1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2019-04-03 | — | — | EP | disclosed |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-05 | — | — | US | disclosed |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-05 | — | — | US | disclosed |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-05 | — | — | US | disclosed |
| US-9845331-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-12-19 | — | — | US | disclosed |
| US-9845331-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-12-19 | — | — | US | disclosed |
| US-9845331-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-12-19 | — | — | US | disclosed |
| WO-2017001354-A1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2017-01-05 | — | — | WO | disclosed |
| US-20160376287-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-12-29 | — | — | US | disclosed |
| US-20160376287-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340592-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | CYP1A2 3573/4885KDM4E 489/4885ALDH1A1 4269/4885 |
| US-20210171541-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | CYP1A2 3573/4885KDM4E 489/4885ALDH1A1 4269/4885 |
| US-20160376287-A1 | Chemical Compounds | CDK9, BCL9, BCL9L | CYP1A2 3573/4885KDM4E 489/4885ALDH1A1 4269/4885 |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | CYP1A2 3573/4885KDM4E 489/4885ALDH1A1 4269/4885 |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | CDK9, BCL9, CDK19 | CYP1A2 3506/4885KDM4E 509/4885ALDH1A1 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.